Evelo Biosciences
2014
FOUNDED
PUBLIC
STATUS
71-80
EMPLOYEES
EVLO
STOCK SYMBOL
1
INVESTMENTS
$7.48
SHARE PRICE
(As of Friday Closing)
Description
Evelo Biosciences Inc operates as a bio-technology company. It is an immuno-microbiome company, develops immunotherapies for the treatment of cancer, autoimmune, and inflammatory diseases. The company develops therapies for the treatment of the gut-body network.
Website
Formerly Known As
Evelo Therapeutics, VL28
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 620 Memorial Drive
- Suite 200 West
- Cambridge, MA 02139
- United States
+1 (617) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Evelo Biosciences’s full profile, request a free trial.
Evelo Biosciences Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $6.51 - $16.75 | $240M | $7.70 | -$2.32 | 29.3K | 32M |
Evelo Biosciences Financials Summary
|
In Thousands,
USD |
TTM
31-Mar-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 119,344 | 385,037 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (67,042) | (56,574) | (26,998) | (12,550) |
| Net Income | (66,745) | (56,946) | (28,047) | (13,332) |
| Total Assets | 141,934 | 159,867 | 43,788 | 18,570 |
| Total Debt | 10,458 | 12,305 | 9,966 | 9,931 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Evelo Biosciences Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Evelo Biosciences‘s full profile, request access.
Request full access to PitchBookEvelo Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Evelo Biosciences‘s full profile, request access.
Request full access to PitchBookEvelo Biosciences Competitors (81)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| UNUM Therapeutics | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 000000000 | 00000 |
| 00000 000000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 000000000 | 00000 |
| 000000000 | Formerly VC-backed | Exton, PA | 000 | 0000 | 000000&0 | 0000 |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000000 | 00000 |
| 00000000000 | Formerly VC-backed | Rockville, MD | 000 | 00000 | 00000000000 | 00000 |
Evelo Biosciences Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 00000000000 | 12-Jul-2016 | 000000000000000000 | Biotechnology | 0000000000 0000 00.0 |
Evelo Biosciences Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Evelo Biosciences‘s full profile, request access.
Request full access to PitchBookEvelo Biosciences Executive Team (13)
2 Former Executives
You’re viewing 5 of 13 executives. Get the full list »Evelo Biosciences Board Members (8)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Balkrishan Gill Ph.D | Evelo Biosciences | Chief Executive Officer, President & Board Member | 000 0000 | |
| David Berry Ph.D | Flagship Pioneering | Board Member & Co-Founder | 000 0000 | |
| David Epstein | Flagship Pioneering | Board Member | 000 0000 | |
| David Perry | Self | Director | 000 0000 | |
| Mark Pruzanski MD | Self | Board Member | 000 0000 |
1 Former Board Member
You’re viewing 5 of 8 board members. Get the full list »